Ignite Creation Date:
2025-12-24 @ 4:47 PM
Ignite Modification Date:
2026-01-07 @ 6:15 PM
Study NCT ID:
NCT06637150
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-15
First Post:
2024-09-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
Sponsor:
Fudan University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCHBCC-N081
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None